Overview

Phase II Study of ASP3550 in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc